Hematuria Treatment Market Research Report -Forecast to 2030

Hematuria Treatment Market Share, Insights And Growth Analysis By Type (Gross, Microscopic And Others), By Causes (Kidney Stones, Prostate Cancer, And Urethritis), By Treatment (Drugs And Therapies), By End-Users (Hospitals, Clinics, And Labs) - Forecast Till 2030

ID: MRFR/MED/1200-HCR | 85 Pages | Published By Kinjoll Dey on March 2023         

Hematuria Treatment Market Speak to Analyst Request a Free Sample

Hematuria Treatment Market Outlook


The hematuria treatment market is expected to reach USD 1,103.8 Million by 2030 at 2.7% CAGR during the forecast period 2022-2030. Hematuria, as a part of the global market, is the presence of blood in a person’s urine. Several causes lead to the presence of blood in the urine of an individual such as urinary tract infections, bladder or kidney stones, and others like kidney infections (pyelonephritis), cancer, enlarged prostate, kidney injury, and the development of kidney disease, as well. Further, there have been various improvements in understanding of the physiological mechanism that can be held responsible for hematuria that has led to developments in the treatment of the medical condition.


The use of antibiotics prescribed for the treatment by doctors is dependent on what part of the track is to be treated or the part where the problem persists. However, the regular developments that occur in route of administration and different concentrations of drugs enable the prevention of the occurrence of the disease or infection to spread to cellular and molecular levels within the body.


COVID 19 Analysis


The sudden outbreak of the fatal coronavirus pandemic has been a major cause of concern for the functionings and treatment extended by the hematuria treatment market in the global scenario for the ongoing forecast period. The arrival of the pandemic has a major disruption in the demand and supply chain mechanism of the global market and the medical professionals are purely dedicated to the treatment of patients that have fallen to the fatalities of the pandemic followed by the rising cases and the non-stop waves of the pandemic of the different infection variants. The operation theaters and other medical rooms are focusing on treating the covid positive patients on priority and the team of doctors and other medical staff is dedicating their services to treat them.


The lockdown that has been imposed followed by the restrictions and social norms that are further creating issues for the expansion of the hematuria treatment market especially during the ongoing forecast period. However, as the number of positive cases is reducing, medical professionals and doctors can physically treat the people who are witnessing other issues. Further, there has been a rise in the research and developments in the medical field that is likely to add to the needful requirements of the market at this hour and hence, play an important role in its expansion in the global hematuria treatment market scenario especially during the ongoing forecast period.


Hematuria Treatment Market Dynamics


Drivers


There has been a rising incidence of hematuria increases with people that belong to the age group of above 35 years of age are more likely to develop the symptoms of hematuria. According to the information that has been circulated by the International Incontinence Society, 70% to 80% of people aged 80 years experiences symptoms of an overactive functioning of the bladder. The substantial rise in the geriatric population is expected to increase the patient pool globally, which in turn is projected to propel the global growth of the hematuria treatment market during the forecast period. According to the information of the World Health Organization (WHO), the global geriatric population is anticipated to reach around an approximate figure of 2 billion that accounts for 22% of the global population by 2050 as compared to 617 million in the historic period of 2015.


Restraints


However, the arrival of the pandemic followed by the decline in the availability of medical professionals to offer hematuria treatment is likely to hamper the operations and the anticipated market growth that has been set for the forecast period that will be ending in 2027. Also, the lockdown has resulted in the disruption of the management and market functioning followed by the lack of awareness and knowledge about the treatment is likely to pose as major restraints that might hamper the global market growth.


The rising role of technology followed by the high prevalence of diseases such as UTI and kidney stones is likely to help in the positive expansion of the hematuria treatment market during the ongoing forecast period. There has been an increase in the incidence of hematuria among various categories of adults, followed by a surge in awareness, extensive research, expansion, and development activities. The prominent advent of high-throughput screening (HTS) for drug discovery, along with the FDA approvals for drugs are the major factors driving the global size of the hematuria treatment market. Currently, the societal cost of UTI infections that extend to health care costs and time missed from work, is estimated to have reached around US$ 3.5 Bn per year in the U.S. alone.


Hematuria Treatment Market Segment Overview


The hematuria treatment market has been segmented based on the following to meet the varied needs of the global target audience that is spread in a series of locations that are participating in the market functioning.


Based on the Drug Type



  • Quinolones

  • Penicillin & combinations

  • Cephalosporin

  • Nitrofurans

  • others


Based on the Disease Type



  • Gross Hematuria

  • Microscopic Hematuria


Based on the Route of Administration



  • Oral

  • Intravenous

  • Others


Based on the Distribution Channel



  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies


Hematuria Treatment Market Regional Analysis


In terms of region, the global hematuria treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, as well. The North American region that consists of prominent regions like the US and Canada is projected to be the most attractive market for hematuria treatment during the forecast period. There has been an early adoption of branded products, followed by other factors like favorable medical reimbursement policies, recent FDA approvals, alongside a large number of drugs in the pipeline, rising focus on reducing the number of undiagnosed hematuria cases, and the availability of early treatment are factors anticipated to drive the hematuria treatment market in the U.S. and Canada during the forecast period.


Hematuria Treatment Market Competitive Landscape


The global hematuria treatment market was reported to have been highly fragmented in the historic forecast period that had ended in 2018. The prominent key manufacturers that are operating in the global market are mentioned as follows:



  • Pfizer, Inc.

  • GlaxoSmithKline, Inc.

  • AstraZeneca plc

  • Boehringer Ingelheim GmbH

  • Johnson & Johnson

  • Cipla Ltd.

  • Hoffmann La Roche Ltd.

  • Bristol Myers Squibb

  • Novartis International AG.

  • Teva Pharmaceutical Industries Ltd.

  • Novartis International AG

  • Merck & Co.


Recent Developments


There has been a huge and considerable increase in the number of hematuria therapeutics that are being dispensed through retail pharmacies and it is being followed by the growth in the number of retail pharmacies that are coming into existence in the developing countries which are likely to help make a huge consideration in the market especially during the ongoing forecast period.


The global patients that are located in various market locations prefer retail pharmacies to purchase drugs, as these are easily accessible. The production and manufacturing firms are focusing on easy availability that is helpful for the hematuria treatment market function expansion in the global market premises.


The European region is projected to emerge as the second most attractive market for hematuria treatment. The functioning in the regional markets that are present in the region is driven by the substantial increase in demand for new therapeutics, and other prominent factors like the carrying of extensive research in the field of urinary tract infection care, followed by the geographical expansion of market players.


Hematuria Treatment Market Report Overview


The global market report aims to highlight the functioning of the global market followed by the market dynamics in the form of drivers and restraints that are likely to impact and introduce a change in the global market functioning. Further, the report has been prepared to give market insights to the investors and help them understand the market competition for them to decide. The report carries in-depth research of the role of the key market players and the recent developments undertaken during the period owing to the rising demands for the market processes and functioning.



Report Scope:

Report Attribute/Metric Details
  Market Size   1,103.8 Million
  CAGR   2.7%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Causes, Treatment, and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   AstraZeneca Plc. Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Novartis International AG, Pfizer, Inc., Sun Pharmaceutical Industries Limited, The Medicines Company, and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Rising frequency rate in numerous types of hematuria
  • Increasing awareness


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The outlook of the hematuria treatment market looks very promising.

    Huge investments for the development of products related to hematuria treatment, rising prevalence of hematuria and increasing awareness, evolving technology such as point-of-care drug delivery systems and focus on delivering best possible care, and rise in the global economy that is widening the access to the quality care are the major tailwinds pushing the growth of the hematuria treatment market.

    North America holds the largest share in the hematuria treatment market, followed by Europe and the Asia Pacific, respectively.

    Bristol-Myers Squibb, AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., GlaxoSmithKline Inc., Merck & Co., Pfizer, Inc., Novartis International AG, Sun Pharmaceutical Industries Limited, and The Medicines Company, are some of the major players operating in the hematuria treatment market.

    Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global hematuria treatment market adopt to gain a larger competitive advantage.